Claims
- 1. An isolated nucleic acid molecule encoding a vertebrate vhh-1 protein.
- 2. An isolated DNA molecule of claim 1.
- 3. An isolated cDNA molecule of claim 2.
- 4. An isolated nucleic acid molecule of claim 1, wherein the nucleic acid molecule encodes a frog vhh-1 protein.
- 5. An isolated nucleic acid molecule of claim 1, wherein the nucleic acid molecule encodes a mammalian vhh-1 protein.
- 6. An isolated nucleic acid molecule of claim 1, wherein the nucleic acid molecule encodes a rat vhh-1 protein.
- 7. An isolated nucleic acid molecule of claim 1, wherein the nucleic acid molecule encodes a human vhh-1 protein.
- 8. An isolated DNA molecule of claim 4, 5, 6 or 7.
- 9. An isolated cDNA molecule of claim B.
- 10. A vector comprising the nucleic acid molecule of claim 1.
- 11. A plasmid comprising the vector of claim 10.
- 12. The plasmid of claim 11, designated pMT21 2hh #7 (ATCC Accession No. 75686).
- 13. An expression plasmid comprising the nucleic acid molecule of claim 1.
- 14. The plasmid of claim 13, which is designated cmv vhh 7 (ATCC Accession No. 73685).
- 15. A mammalian cell comprising the plasmid of claim 11 or 13.
- 16. The mammalian cell of claim 12, wherein the cell is a Cos cell.
- 17. A nucleic acid probe comprising a nucleic acid molecule of at least 15 nucleotides capable of specifically hybridizing with a unique sequence included within the sequence of a nucleic acid molecule comprising the gene encoding the vertebrate vhh-1 protein.
- 18. The nucleic acid probe of claim 17, wherein the nucleic acid molecule is a DNA molecule.
- 19. A purified vertebrate vhh-1 protein.
- 20. A purified unique polypeptide fragment of the vertebrate vhh-1 protein of claim 19.
- 21. A purified frog vhh-1 protein.
- 22. A purified mammalian vhh-1 protein.
- 23. A purified unique polypeptide fragment of the mammalian vhh-1 protein of claim 22.
- 24. A purified human vhh-1 protein.
- 25. A monoclonal antibody directed to a vertebrate vhh-1 protein.
- 26. A monoclonal antibody of claim 25 directed to a frog vhh-1 protein.
- 27. A monoclonal antibody of claim 25 directed to a mammalian vhh-1 protein.
- 28. A monoclonal antibody of claim 25 directed to a rat vhh-1 protein.
- 29. A monoclonal antibody of claim 25 directed to a human vhh-1 protein.
- 30. Polyclonal antibodies directed to a vertebrate vhh-1 protein.
- 31. A transgenic nonhuman mammal which comprises an isolated DNA molecule of claim 2.
- 32. The transgenic nonhuman mammal of claim 31, wherein the DNA encoding a vertebrate vhh-1 protein is operatively linked to a tissue specific regulatory elements.
- 33. A method of determining the physiological effects of expressing varying levels of vertebrate vhh-1 protein which comprises producing a panel of transgenic nonhuman animals each expressing a different amount of vertebrate vhh-1 protein.
- 34. A method of producing the isolated protein of claim 19 which comprises:
a. inserting nucleic acid molecule encoding the vertebrate vhh-1 protein in a suitable vector; b. introducing the resulting vector in a suitable host cell; c. selecting the introduced host cell for the expression of the vertebrate vhh-1 protein; d. culturing the selected cell to produce the vhh-1 protein; and e. recovering the vhh-1 protein produced.
- 35. A method of inducing the differentiation of floor plate cells comprising contacting floor plate-cells with the purified vertebrate vhh-1 protein of claim 19 at a concentration effective to induce the differentiation of floor plate cells.
- 36. A method of inducing the differentiation of floor plate cells in a subject comprising administering to the subject the purified vertebrate vhh-1 protein of claim 19 at an amount effective to induce the differentiation of floor plate cells in the subject.
- 37. A method of inducing the differentiation of motor neuron comprising contacting the floor plate cells with the purified vertebrate vhh-1 protein of claim 19 at a concentration effective to induce the differentiation of motor neuron.
- 38. A method of inducing the differentiation of motor neuron in a subject comprising administering to the subject the purified vertebrate vhh-1 protein of claim 19 at an amount effective to induce the differentiation of motor neuron in the subject.
- 39. A method of generating ventral neurons comprising contacting progenitor cells with the purified vertebrate vhh-1 protein of claim 19 at a concentration effective to generate ventral neurons.
- 40. A method of generating ventral neurons from progenitor cells in a subject comprising administering to the subject the purified vertebrate vhh-1 protein of claim 19 at an amount effective to generate ventral neurons from progenitor cells in the subject.
- 41. A pharmaceutical composition comprising a purified vertebrate vhh-I protein of claim 19 and a pharmaceutically acceptable carrier.
- 42. A pharmaceutical composition comprising a purified mammalian vhh-1 protein of claim 22 and a pharmaceutically acceptable carrier.
- 43. A pharmaceutical composition comprising a purified human vhh-1 protein of claim 23 and a pharmaceutically acceptable carrier.
- 44. A pharmaceutical composition comprising a purified human vhh-1 protein of claim 24 and a pharmaceutically acceptable carrier.
- 45. A method for treating a human subject afflicted with an abnormality associated with a lack of one or more normally functioning motor neurons which comprises introducing an amount or pharmaceutical composition of claim 41, 42, 43 or 44 effective to generate motor neurons from undifferentiated motor neuron precursor cells in a human, thereby treating a human subject afflicted with an abnormality associated with a lack of one or more normally functioning motor neurons.
- 46. A method of treating a human subject afflicted with a neurodegenerative disease which comprises introducing an amount of pharmaceutical composition of claim 41, 42, 43, or 44 effective to generating motor neurons from undifferentiated precursor cells in a human, thereby treating the human subject afflicted with a neurodegenerative disease.
- 47. The method of claim 46 wherein the generation of motor neurons from undifferentiated precursor neurons alleviates a chronic neurodegenerative disease.
- 48. The method of claim 47 wherein the chronic neurodegenerative disease is Amyotropic lateral sclerosis (ALS).
- 49. A method of treating a human subject afflicted with an acute nervous system injury which comprises introducing an amount of pharmaceutical composition of claim 41, 42, 43, or 44 effective to generate motor neurons from undifferentiated precursor cells in a human, thereby treating a human subject afflicted with an acute nervous system injury.
- 50. The method of claim 49 wherein the acute nervous system injury is localized to a specific central axon which comprises surgical implantation of a pharmaceutical compound comprising a vhh-1 protein and a pharmaceutically acceptable carrier effective to generate motor neurons from undifferentiated motor neurons located proximal to the injured axon, thereby alleviating the acute nervous system injury localized to a specific central axon.
Parent Case Info
[0001] This application is a continuation-in-part to U.S. patent application Ser. No. 08/202,040, filed Feb. 25, 1994, the contents of which are hereby incorporated by reference.
Government Interests
[0002] The invention disclosed herein was made with U.S. Government support under Grant Number NS-30532 from the National Institute of Health, U.S. Department of Health and Human Servies. Accordingly, the U.S. Government has certain rights in this invention.
Divisions (1)
|
Number |
Date |
Country |
Parent |
08700393 |
Feb 1997 |
US |
Child |
10411927 |
Apr 2003 |
US |